STOCK TITAN

Insight Molecular Diagnostics insider buys $6M in shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

At Insight Molecular Diagnostics Inc. (IMDX), 10% owner Broadwood Partners, L.P. purchased 3,428,571 common shares from the company in an underwritten public offering on November 17, 2026, for $1.75 per share and a total purchase price of $5,999,999.25. No Rule 10b5-1 plan is reported. A related indirect ownership entry lists 16,113,455 shares following the transaction. The report also lists currently exercisable warrants for 150,093 common shares at $30.60, expiring April 19, 2027. Broadwood Capital, Inc., Broadwood Partners' general partner, and Neal C. Bradsher, a 10% owner and president of Broadwood Capital, may be deemed beneficial owners. Each reporting person disclaims beneficial ownership except to the extent of its or his pecuniary interest.

Insider BROADWOOD PARTNERS, L.P., BROADWOOD CAPITAL INC, Bradsher Neal C
Role 10% Owner | 10% Owner | 10% Owner
Bought 3,428,571 shs ($6.00M)
Increase in Position 27.0%
Type Security Shares Price Value
Purchase Common Stock, no par value F3, F1 3,428,571 $1.75 $6.00M
Purchase Common Stock, no par value F1 0 $0.00 $0.00
Holding Warrant to Purchase Common Stock F4, F1 -- -- --
Holding Warrant to Purchase Common Stock F4, F1 -- -- --
Holding Common Stock, no par value F2 -- -- --
Holdings After Transaction: Common Stock, no par value — 16,113,612 shares (Direct); Common Stock, no par value — 16,113,455 shares (Indirect, Footnote); Warrant to Purchase Common Stock — 150,093 warrants (Direct); Warrant to Purchase Common Stock — 150,093 warrants (Indirect, Footnote)
Holdings Before and After: Common Stock, no par value, 12,685,041 to 16,113,612 shares (Direct); Common Stock, no par value, 16,113,455 to 16,113,455 shares (Indirect, Footnote)
Footnotes (4)
  1. F1. The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  2. F2. These securities are directly owned by Neal C. Bradsher.
  3. F3. On November 17, 2026, Broadwood Partners purchased 3,428,571 shares of Common Stock, no par value (the "Common Shares"), of Insight Molecular Diagnostics Inc. (the "Issuer") from the Issuer in an underwritten public offering for a total purchase price of $5,999,999.25, or $1.75 per Common Share.
  4. F4. These warrants are currently exercisable.
Common shares purchased 3,428,571 shares Broadwood Partners purchase on November 17, 2026
Purchase price per share $1.75 per share Broadwood Partners purchase on November 17, 2026
Total purchase price $5,999,999.25 Broadwood Partners purchase on November 17, 2026
Common shares following transaction 16,113,455 shares Reported in a related indirect ownership entry on November 17, 2026
Warrant underlying shares 150,093 shares Reported warrants; currently exercisable and expiring April 19, 2027
Warrant exercise price $30.60 Reported warrants expiring April 19, 2027
underwritten public offering financial
"in an underwritten public offering"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
beneficially owned regulatory
"may be deemed to be beneficially owned"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
pecuniary interest regulatory
"to the extent of its or his pecuniary interest therein"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IMDX shares did Broadwood Partners buy, and at what price?

Broadwood Partners, L.P. bought 3,428,571 shares at $1.75 per share from Insight Molecular Diagnostics Inc. on November 17, 2026, in an underwritten public offering. The total purchase price was $5,999,999.25. No Rule 10b5-1 plan is reported.

What warrant position did the IMDX ownership report list?

It lists warrants exercisable for 150,093 common shares at $30.60, with an expiration date of April 19, 2027. The warrants are currently exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BROADWOOD PARTNERS, L.P.

(Last)(First)(Middle)
C/O BROADWOOD CAPITAL INC
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Insight Molecular Diagnostics Inc. [ IMDX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock, no par value11/17/2026P3,428,571A$1.75(3)16,113,455D(1)
Common Stock, no par value11/17/2026P0A$016,113,455IFootnote(1)
Common Stock, no par value157D(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrant to Purchase Common Stock$30.6 (4)04/19/2027Common Stock150,093150,093D(1)
Warrant to Purchase Common Stock$30.6 (4)04/19/2027Common Stock150,093150,093IFootnote(1)
1. Name and Address of Reporting Person*
BROADWOOD PARTNERS, L.P.

(Last)(First)(Middle)
C/O BROADWOOD CAPITAL INC
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
BROADWOOD CAPITAL INC

(Last)(First)(Middle)
156 WEST 56TH STREET
3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
1. Name and Address of Reporting Person*
Bradsher Neal C

(Last)(First)(Middle)
C/O BROADWOOD CAPITAL INC
156 WEST 56TH STREET, 3RD FLOOR

(Street)
NEW YORK NEW YORK 10019

(City)(State)(Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer
DirectorX10% Owner
Officer (give title below)Other (specify below)
Explanation of Responses:
1. The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
2. These securities are directly owned by Neal C. Bradsher.
3. On November 17, 2026, Broadwood Partners purchased 3,428,571 shares of Common Stock, no par value (the "Common Shares"), of Insight Molecular Diagnostics Inc. (the "Issuer") from the Issuer in an underwritten public offering for a total purchase price of $5,999,999.25, or $1.75 per Common Share.
4. These warrants are currently exercisable.
Broadwood Partners, L.P., By: Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President11/19/2026
Broadwood Capital, Inc., By: /s/ Neal C. Bradsher, President11/19/2026
Neal C. Bradsher, /s/ Neal C. Bradsher11/19/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading